Eli Lilly and Company
INDIANAPOLIS, December 8, 2011 -
- Eli Lilly and Company launching global disease awareness campaign in more than 15 countries to encourage men to talk to their doctors about erectile dysfunction (ED)
An international survey sponsored by Eli Lilly and Company (NYSE: LLY) found large cultural differences between European, Asian and North American countries when it comes to men and women discussing sexual health issues with their doctors.
INDIANAPOLIS, October 28, 2011 -
Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted marketing authorization for the use of ALIMTA (pemetrexed for injection) as continuation maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
LILLE, France, October 27, 2011 -
- Funding Continues Partnership's Fight against Multidrug-Resistant Tuberculosis
The Eli Lilly and Company Foundation has committed US $30 million in funding to further support The Lilly MDR-TB Partnership in its fight against multidrug-resistant tuberculosis - a disease that disproportionately affects developing countries and kills more than 150,000 people each year.
INDIANAPOLIS, October 25, 2011 -
Eli Lilly and Company (NYSE: LLY) announces withdrawal of its Xigris [drotrecogin alfa (activated)] product in all markets following results of the PROWESS-SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock.
INDIANAPOLIS, September 26, 2011 -
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of ALIMTA (pemetrexed for injection) as continuation maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
More News
- Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases
- New ESC Guidelines Recommend Efient (Prasugrel) as First-line Antiplatelet Therapy for Patients with Non-ST Segment Myocardial Infarction and Unstable Angina Acute Coronary Syndromes
- Efient (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study
- Eli Lilly India and Lupin Announce Strategic Collaboration to Help Fight the Battle Against Diabetes
- Lilly Global Giving Puts Power of Philanthropy in Employees’ Hands
- New Study Released Today Shows Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
- Exenatide Once Monthly Showed Positive Results in Phase 2 Study
- Lechleiter Delivers Keynote Address at 2011 Pharma Summit
- Decision does not affect other Lilly Alzheimer's compounds in development
- Deal Provides Strategic Fit For Elanco, Lilly's Animal Health Division
- Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
- Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
- Eight out of 10 People Diagnosed With Heart Disease Consider Their Diagnosis a ‘Wake-Up Call’
- Eli Lilly and Company Announces New Drug Discovery Initiative
- Lilly Advances Second Alzheimer’s Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
